Protagonist Therapeutics (PTGX) Projected to Announce Earnings on Thursday

Protagonist Therapeutics (NASDAQ:PTGX) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $2.50 per share and revenue of $238.49 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.02. The company had revenue of $213.47 million during the quarter, compared to analysts’ expectations of $212.03 million. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%. Protagonist Therapeutics’s revenue for the quarter was up 3746.8% compared to the same quarter last year. On average, analysts expect Protagonist Therapeutics to post $4.59 EPS for the current fiscal year and $0.11 EPS for the next fiscal year.

Protagonist Therapeutics Price Performance

NASDAQ PTGX opened at $139.37 on Tuesday. The company has a market cap of $9.02 billion, a P/E ratio of 138.00 and a beta of 1.53. The stock has a 50-day moving average of $142.63 and a two-hundred day moving average of $116.76. Protagonist Therapeutics has a 1-year low of $75.44 and a 1-year high of $160.81.

Wall Street Analyst Weigh In

Several research analysts have recently commented on PTGX shares. Citigroup raised their price objective on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Weiss Ratings downgraded shares of Protagonist Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Wall Street Zen lowered shares of Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 10th. TD Cowen raised their price target on shares of Protagonist Therapeutics from $155.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Finally, The Goldman Sachs Group upgraded shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $110.00 to $186.00 in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Buy” and a consensus target price of $163.27.

Insider Activity

In related news, CEO Dinesh V. Ph D. Patel sold 65,761 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $149.11, for a total transaction of $9,805,622.71. Following the sale, the chief executive officer directly owned 523,478 shares in the company, valued at approximately $78,055,804.58. This represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the completion of the sale, the chief financial officer directly owned 59,003 shares in the company, valued at approximately $8,365,445.34. This trade represents a 49.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 283,629 shares of company stock valued at $41,443,786 in the last quarter. Company insiders own 5.19% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a biopharmaceutical company focused on discovering and developing peptide-based medicines for immune-mediated and hematologic diseases. The company uses its proprietary peptide technology platform to design therapies intended to act on specific biological pathways and receptors.

Its leading program is icotrokinra, also known as JNJ-2113, an oral, targeted inhibitor of the interleukin-23 receptor being developed in collaboration with Janssen Pharmaceuticals for inflammatory and immune-mediated conditions, including psoriasis and inflammatory bowel diseases.